Ascletis Announces First Participants with Obesity or Overweight Dosed in Its U.S. 12-week Phase IIa Study Evaluating Once-Month

• click to rate

  Posted by Two Blokes Mon at 3:00 AM - Filed in Stock - 1 view
  
  -          First p articipants with obesity or o verweight w ith at least one w eight- r elated c omorbidity have been d osed in a U.S. 12-week Phase IIa study with once-monthly subcutaneous  (SQ)  depot formulation of s mall m olecule GLP-1  receptor a gonist ASC30. -          Ultra-long-acting SQ  depot formulation of small molecule ASC30 demonstrated a 36-day half-life in participants with obesity in the Phase Ib study, supporting once monthly administration.